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The well treated HIV population remains at risk for insulin resistance and chronic immune activation. We tested the effects of acute hyperinsulinemia on inflammation in HIV. Twenty HIV-infected and 10 non-HIV-infected individuals well matched for BMI underwent oral glucose tolerance testing to stimulate insulin secretion and assess for changes in circulating soluble CD163, soluble CD14, and monocyte chemoattract protein 1. Soluble CD14 decreased significantly after stimulation of hyperinsulinemia and no significant changes in soluble CD163 or monocyte chemoattract protein 1 were demonstrated in HIV-infected and non-HIVinfected groups.
Shifts toward an increasing monocyte population in chronic well treated HIV infection [1] are correlated with insulin resistance. Although a pathologic link between insulin resistance and inflammation has been reported, the exact directionality and causality of this relationship remains unclear. As systemic hyperinsulinemia evolves in a state of insulin resistance, we took advantage of standardized oral glucose tolerance testing (OGTT) to physiologically stimulate endogenous insulin secretion and assess for parallel changes in systemic soluble CD163 (sCD163), soluble CD14 (sCD14), and monocyte chemoattract protein 1 (MCP-1) among HIV-infected and non-HIV-infected groups. We hypothesized that excess insulin would enhance macrophage-driven inflammation in HIV, an important question to address, as such data could direct treatment toward insulin-sensitizing strategies to dampen inflammatory-mediated metabolic sequelae in HIV.
Twenty HIV-infected and 10 non-HIV-infected individuals were recruited to be of similar age (18-65 years), sex, and waist circumference. Individuals with known diabetes, cardiovascular disease or pregnancy were excluded. All individuals provided institutional review board-approved informed consent to participate.
A standard 75 g OGTT was performed in the morning following a 12-h fast. Measurements of plasma glucose and serum insulin were obtained at 0 and 120 min.
EDTA plasma was collected at 0 and 120 min during the OGTT. ELISA was performed to quantify sCD163 (Trillium Diagnostics, Bangor, Maine, USA), sCD14 and MCP-1 (R&D Systems, Minneapolis, Minnesota, USA), key immune markers in HIV well recognized for their relevance to insulin resistance and metabolic dysregulation [2] [3] [4] [5] [6] .
Data are presented as mean AE SEM if normally distributed or median (interquartile range) if nonnormally distributed. Paired within-group (HIV or non-HIV) or between-group comparisons of the absolute change in glycemic and immune parameters at baseline and 120 min of the OGTT were assessed using the appropriate test (Student's t test or Wilcoxon test).
HIV-infected and non-HIV-infected groups were of similar age and sex. Individuals with HIV had a chronic history of infection (18 AE 1 years) and antiretroviral therapy use (11 AE 1 years) and demonstrated good immunological control (CD4 þ 571 AE 73 cells/ml). Body composition, including BMI (26 AE 1 vs. 25 AE 1 kg/m 2 , P ¼ 0.65, HIV vs. non-HIV), and other metabolic parameters did not differ based on serostatus (Supplemental Table 1 , http://links.lww.com/QAD/B108).
Fasting glucose (84 AE 1 vs. 87 AE 1 mg/dl, P ¼ 0.08) and insulin (4 [3, 9] vs. 3 [2, 7] uIU/ml, P ¼ 0.14) were comparable between both HIV-infected and non-HIVinfected groups. At 120 min, glucose levels rose to similar levels within each group (129 AE 8 vs. 114 AE 11 mg/dl, change glucose P 0.0001 and P ¼ 0.04, HIV and non-HIV). Insulin levels at 120 min [49 (39,73) vs. 19 (8,46) uIU/ml] were higher in HIV-infected vs. non-HIV-infected groups (P ¼ 0.03). The absolute change in insulin during the OGTT was significantly increased within-group (change insulin P 0.0001 and P ¼ 0.002, HIV and non-HIV) and between-group (P ¼ 0.03), in which the absolute glucose change was similar betweengroups (P ¼ 0.21) ( Table 1) . sCD14 levels at baseline [1927 (1433,2172) vs. 1360 (1288,1521) pg/ml, P ¼ 0.005] and 120 min [1756 (1473,2059) vs. 1333 (1177,1502) pg/ml, P ¼ 0.002] were significantly higher in HIV-infected vs. non-HIVinfected individuals. sCD14 significantly decreased within both the HIV-infected (P ¼ 0.04) and non-HIV-infected (P ¼ 0.049) groups during the OGTT, while there was no significant between-group change. Baseline MCP-1 and sCD163 were similar regardless of serostatus, and there was no considerable change noted within-group or between-group during the OGTT for sCD163 and MCP-1 (all P > 0.05) ( Table 1 ).
The current study utilizing the OGTT assessed, for the first time, the effects of acute hyperinsulinemia on immune markers among HIV-infected and non-HIVinfected groups. Our testing demonstrated an expected overall increase in glucose and insulin levels among all patients after 120 min. The significantly greater rise in insulin levels during the OGTT among HIV-infected vs. non-HIV-infected individuals reflects known physiology among the HIV population whom demonstrate an increased risk of insulin resistance compared with the agematched and BMI-matched non-HIV population [7] . In contrast to changes in glycemic parameters, there was a significant decrease in sCD14 after stimulation of hyperinsulinemia through glucose loading in both the HIV-infected and non-HIV-infected groups. In addition, sCD163 appeared to decrease in both groups during the OGTT, though not to a significant degree.
Similar studies investigating inflammation during OGTT in the obese and diabetes populations have generated mixed results, with hyperinsulinemia having decreased, increased or neutral effects on markers of generalized inflammation and immune activation [8, 9] . As some evidence suggests insulin resistance is monocyte and macrophage-mediated through inhibition of insulin signaling pathways or impaired GLUT4 translocation [10] , we may have anticipated neutral effects of insulin on immune markers during the OGTT if this were an exclusive and unidirectional relationship. Other data demonstrate that insulin may fuel monocyte and macrophage activation in the adipose depot, evidenced by increases in circulating immune markers [11, 12] .
Contrary to this and our hypothesis, we did not see a significant increase in immune markers, but rather a decrease in sCD14 and possibly sCD163. The similar change among both HIV-infected and non-HIV-infected individuals suggests this phenomenon occurs regardless of serostatus. Greater differences within and between serostatus groups may have resulted had we enrolled individuals with severe insulin resistance.
In support of our findings demonstrating reduced sCD14 during a state of hyperinsulinemia, insulin is reported to have direct anti-inflammatory actions by decreasing NFkB or inhibiting toll-like receptor expression [13] . Insulin also indirectly exerts anti-inflammatory effects on metabolic disease by lowering glucose and inhibiting lipolysis-generated fatty free acids. Taken together, these evidence build upon a novel biologic concept, such that hyperinsulinemia may have salutary effects, acting to dampen chronic inflammation in the well treated HIV population whom remain at dual risk for inflammation and insulin resistance.
A limitation of the study includes the small sample size. The focus of our investigation was evaluating acute rather than chronic effects of hyperinsulinemia on immune activation. In addition, changes in immune activation should be evaluated for effects on insulin resistance. To that end, a more sophisticated biologic cross-talk may exist, such that insulin and monocyte/macrophagederived inflammation feedback (whether negative or positive) on one another during HIV infection.
The main strength of this study was our ability to further investigate the directionality and causality of a correlative relationship, using a physiologic intervention to stimulate 
